Current Report Filing (8-k)
December 21 2022 - 4:46PM
Edgar (US Regulatory)
0001725255
false
0001725255
2022-12-15
2022-12-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 15, 2022
AdaptHealth
Corp.
(Exact name
of registrant as specified in its charter)
| Delaware | |
001-38399 | |
82-3677704 |
(State or other jurisdiction of
incorporation) | |
(Commission File Number) | |
(IRS Employer Identification No.) |
|
220 West Germantown Pike, Suite 250
Plymouth Meeting, PA |
|
19462 |
| (Address of principal executive offices) |
|
(Zip Code) |
| |
|
|
| (610) 424-4515 |
(Registrant’s telephone number, including area code)
|
Not Applicable |
|
(Former name or former address, if changed
since last report.) |
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to
Section 12(b) of the Act:
|
Title of each
class |
Trading Symbol(s) |
Name of each
exchange on which registered |
| Common Stock, par value $0.0001 per share
|
AHCO
|
The
Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company,
indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
On December 15, 2022, the Board of Directors of AdaptHealth Corp. (the
“Company”) authorized the extension of the Company’s previously announced share repurchase program to allow for common
stock repurchases under the program through December 31, 2023. The Company’s share repurchase program, which, prior to the extension,
was set to expire on December 31, 2022, authorizes the Company to repurchase up to $200 million of the Company’s common stock, of
which approximately $186 million was available as of December 15, 2022.
The timing and actual number of shares to be repurchased in the future
will depend upon market conditions and other factors. Shares may be repurchased from time to time on the open market, through the use
of Rule 10b5-1 plans, through privately negotiated transactions or otherwise. Purchases may be started or stopped at any time without
prior notice depending on market conditions and other factors. The Company intends to fund the share repurchase program through its available
cash and liquidity.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
Dated: December 21, 2022
| |
AdaptHealth Corp. |
| |
|
| |
By: |
/s/ Jason Clemens |
| |
|
Name: Jason Clemens |
| |
|
Title: Chief Financial Officer |
AdaptHealth (NASDAQ:AHCO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AdaptHealth (NASDAQ:AHCO)
Historical Stock Chart
From Apr 2023 to Apr 2024
